Nashville – Lorcaserin is more effective in helping obese patients with type 2 diabetes achieve glycemic control than diet and exercise alone, data from a poster presented at the American Association of Nurse Practitioners 2014 meeting indicate.

The phase 3 BLOOM-DM clinical trial looked at the effects of lorcaserin (Belviq, Eisai Pharmaceuticals) on weight loss, hemoglobin A1c levels and cardiometabolic risk factors. 

The study included 509 patients who were randomly assigned to either lorcaserin or placebo along with diet and exercise. All patients had hemoglobin levels between 7% and 10%, as well as similar fasting plasma glucose (FPG) levels. The researchers defined “responders” as patients who achieved the primary endpoint of weight loss of at least 5% at 52 weeks of treatment.

Continue Reading

Nearly twice as many patients with diabetes in the lorcaserin group achieved hemoglobin levels of less than 7% compared with the placebo group (50.4% vs. 26.3%), even if they did not lose weight, the researchers found.

Measured from baseline, the mean change in FPG and hemoglobin levels in the lorcaserin was -38.1 mg/dL and -1.3, respectively, compared to -26.0 mg/dL and -1.0 in the placebo group.

Those who responded to treatment had overall improved glycemic control and relied less on the use of antihyperglycemic medications compared with those who did not.

When it came to cardiometabolic risk factors, the authors also noted an overall decrease in both systolic and diastolic blood pressure in all groups treated with either lorcaserin or placebo, aside from small increases in systolic BP noted at week 52.

“Glycemic control was substantially improved despite minimal weight loss in lorcaserin non-responders,” the authors concluded. “This observation suggests potential weight-independent effects of lorcaserin on glycemia, which should be studied further.”

Common adverse effects among the treatment arm were hypoglycemia, headache, back pain, cough and fatigue.


  1. Soliman W. “Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and non-responders.” Presented at: American Association of Nurse Practitioners 2014 meeting. June 17-22; Nashville, Tenn.